MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial

M W Rohaan, R Gomez-Eerland,J H van den Berg,M H Geukes Foppen,M van Zon,B Raud, I Jedema, S Scheij,R de Boer, N A M Bakker,D van den Broek, L M Pronk, L G Grijpink-Ongering,A Sari, R Kessels,M van den Haak, H A Mallo, M Karger,B A van de Wiel,C L Zuur,C W Duinkerken, F Lalezari,J V van Thienen, S Wilgenhof,C U Blank,J H Beijnen,B Nuijen,T N Schumacher,J B A G Haanen

Immuno-Oncology and Technology（2022）

引用 8|浏览5

暂无评分

摘要

•Described culture method leads to highly reactive T cells with a memory stem/central memory phenotype.•On-target, off-tumor toxicity was dose-dependent and limited dose escalation.•The maximum tolerated cell dose was 1.0 × 108 gene-modified T cells.•Transfused T cells persisted up to 9 months and was related to cell dose.•Optimization of TCR gene therapy should include strategies to limit on-target, off-tumor toxicity.

查看译文

关键词

adoptive cell therapy,immunotherapy,MART-1,melanoma,T-cell receptor gene therapy,uveal

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要